Skip to main content

Table 2 Expression of Cx30 on astrocytes after different HIV treatments

From: HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS

Cx30 expression in astrocytes (percentage of control, n = 3)
Treatment (virus) 7 days 14 days 21 days 28 days
HIVADA (20 ng/ml) −12.3 ± 9.9* −22.5 ± 8.9* −32 ± 9.88* −38.9 ± 7.9*
HIVJR-CSF (20 ng/ml) −28.7 ± 6.8* −32.7 ± 11* −49.8 ± 14.6* −65.5 ± 21.2*
Treatment (recombinant proteins) 6 h 12 h 24 h 48 h
Vif (1, 100, and 300 ng/ml) −3.8 ± 1.06* −5.99 ± 2.3* −8.88 ± 4.5 * −8.98 ± 5.6*
Gag (p55, p24, or p7: 1, 100, and 300 ng/ml) No change No change No change No change
Rev (1, 100, and 250 ng/ml) No change No change No change No change
Nef (1, 100, and 250 ng/ml) −5.3 ± 3.2* −8.6 ± 3.43* −12.7 ± 6.6* −14.9 ± 7.45*
Gp120 (1, 50, and 100 nM) −3.44 ± 2.1* −5.6 ± 5.4* −8.88 ± 4.3* −9.15 ± 3.3*
HIV-tat1–72 (1, 100, and 300 ng/ml) −9.02 ± 3.3* −10.5 ± 5.4* −17.5 ± 3.9* −28.1 ± 11.8*
IL-1β (10 ng/ml) −21.7 ± 8.9* −36.54 ± 9* −51.3 ± 9.3* −52.3 ± 21.5*
  1. Although we used three different concentrations for each HIV protein, no significant differences were detected among them. Thus, we combined the data from the three different concentrations
  2. *p ≤ 0.05 (n = 4)